Amgen Inc. (BCBA:AMGN)

Market Cap	207.25T
Revenue (ttm)	41.61T
Net Income (ttm)	7.89T
Shares Out	n/a
EPS (ttm)	14,574.49
PE Ratio	26.27
Forward PE	14.44
Dividend	207.33 (1.62%)
Ex-Dividend Date	May 16, 2025

Volume	385
Average Volume	2,177
Open	12,600
Previous Close	12,800
Day's Range	12,600 - 12,800
52-Week Range	9,500 - 14,550
Beta	n/a
RSI	48.67
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD